149 related articles for article (PubMed ID: 3873768)
1. Plasma fibrinolytic activity in patients undergoing major abdominal surgery.
Mellbring G; Dahlgren S; Wiman B
Acta Chir Scand; 1985; 151(2):109-14. PubMed ID: 3873768
[TBL] [Abstract][Full Text] [Related]
2. Levels of fibrinolytic activators and inhibitors in plasma after severe trauma.
Sørensen JV
Blood Coagul Fibrinolysis; 1994 Feb; 5(1):43-9. PubMed ID: 7514044
[TBL] [Abstract][Full Text] [Related]
3. Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor--relationship to deep vein thrombosis and influence of prophylaxis.
Páramo JA; Alfaro MJ; Rocha E
Thromb Haemost; 1985 Oct; 54(3):713-6. PubMed ID: 3937269
[TBL] [Abstract][Full Text] [Related]
4. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
van Giezen JJ; Boon GI; Jansen JW; Bouma BN
Thromb Haemost; 1993 Apr; 69(4):381-6. PubMed ID: 8497851
[TBL] [Abstract][Full Text] [Related]
5. Renal and hepatic handling of endogenous tissue-type plasminogen activator (t-PA) and its inhibitor in man.
Brommer EJ; Derkx FH; Schalekamp MA; Dooijewaard G; vd Klaauw MM
Thromb Haemost; 1988 Jun; 59(3):404-11. PubMed ID: 3142078
[TBL] [Abstract][Full Text] [Related]
6. Diurnal variation of the fibrinolytic system.
Grimaudo V; Hauert J; Bachmann F; Kruithof EK
Thromb Haemost; 1988 Jun; 59(3):495-9. PubMed ID: 3142085
[TBL] [Abstract][Full Text] [Related]
7. Impaired fibrinolysis in obstructive jaundice--evidence from clinical and experimental studies.
Colucci M; Altomare DF; Chetta G; Triggiani R; Cavallo LG; Semeraro N
Thromb Haemost; 1988 Aug; 60(1):25-9. PubMed ID: 3142090
[TBL] [Abstract][Full Text] [Related]
8. [Thromboembolic disease and anomalies of fibrinolysis].
Juhan-Vague I; Aillaud MF; Valadier J; Alessi MC; Serradimigni A
Ann Med Interne (Paris); 1986; 137(6):471-4. PubMed ID: 3101564
[TBL] [Abstract][Full Text] [Related]
9. Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1.
Juhan-Vague I; Vague P; Alessi MC; Badier C; Valadier J; Aillaud MF; Atlan C
Diabete Metab; 1987 Jul; 13(3 Pt 2):331-6. PubMed ID: 3115843
[TBL] [Abstract][Full Text] [Related]
10. Masking of fibrinolytic response to stimulation by an inhibitor of tissue-type plasminogen activator in plasma.
Brommer EJ; Verheijen JH; Chang GT; Rijken DC
Thromb Haemost; 1984 Oct; 52(2):154-6. PubMed ID: 6441302
[TBL] [Abstract][Full Text] [Related]
11. Increased PA-inhibitor levels in the postoperative period--no cause-effect relation with increased cortisol.
Aillaud MF; Juhan-Vague I; Alessi MC; Marecal M; Vinson MF; Arnaud C; Vague P; Collen D
Thromb Haemost; 1985 Aug; 54(2):466-8. PubMed ID: 2417352
[TBL] [Abstract][Full Text] [Related]
12. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.
Hamsten A; Wiman B; de Faire U; Blombäck M
N Engl J Med; 1985 Dec; 313(25):1557-63. PubMed ID: 3934538
[TBL] [Abstract][Full Text] [Related]
13. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis.
Juhan-Vague I; Valadier J; Alessi MC; Aillaud MF; Ansaldi J; Philip-Joet C; Holvoet P; Serradimigni A; Collen D
Thromb Haemost; 1987 Feb; 57(1):67-72. PubMed ID: 3109059
[TBL] [Abstract][Full Text] [Related]
14. Fibrinolysis after application of a pneumatic tourniquet.
Petäjä J; Myllynen P; Myllylä G; Vahtera E
Acta Chir Scand; 1987; 153(11-12):647-51. PubMed ID: 3124428
[TBL] [Abstract][Full Text] [Related]
15. Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis.
Francis RB; McGehee WG; Feinstein DI
Thromb Haemost; 1988 Jun; 59(3):412-4. PubMed ID: 3142079
[TBL] [Abstract][Full Text] [Related]
16. Tissue plasminogen activator and its inhibitor following major surgery in relation to ventilatory pattern.
Eriksson E; Risberg B
Acta Chir Scand; 1988 Jan; 154(1):57-60. PubMed ID: 3128033
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of plasminogen activator in human plasma using the method of fibrin/celite column chromatography--with special reference to the determination of fibrin adsorbable tissue-plasminogen activator by ELISA].
Ieko M
Hokkaido Igaku Zasshi; 1985 Nov; 60(6):834-47. PubMed ID: 4085966
[TBL] [Abstract][Full Text] [Related]
19. Fibrinolytic parameters in patients undergoing total hip replacement: relationship with the development of asymptomatic deep vein thrombosis and diagnostic usefulness of venous occlusion.
Trotti R; Siragusa S; Rondanelli M; Chezzi L; Citterio A; Melzi d'Eril GV; Piovella F
Haematologica; 1997; 82(2):178-81. PubMed ID: 9175322
[TBL] [Abstract][Full Text] [Related]
20. Effects of oral stanozolol used in the prevention of postoperative deep vein thrombosis on fibrinolytic activity.
Sue-Ling HM; Davies JA; Prentice CR; Verheijen JH; Kluft C
Thromb Haemost; 1985 Feb; 53(1):141-2. PubMed ID: 3873118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
